Influence of the dissolution medium on the release of dehydroepiandrosterone from lipophilic suppositories

Open access


Suppositories with cocoa butter containing dehydroepiandrosterone (DHEA) without and with the addition of Span 80 and Tween 80 as surfactants with low and high HLB values were prepared. The physical properties and the drug content of all prepared suppositories were in accordance with the pharmacopoeial requirements. The release study tests in three dissolution media such as water, lactic acid solution at pH 4.2 and phosphate buffer at pH 7.4 were carried out. In acidic and alkalic media only about 10% and 27% of DHEA were released, respectively. The addition of Span 80 to the suppository mass did not improve the release process, but the addition of Tween 80 caused the increase in the amount of DHEA released in the acidic medium to about 35%. The data showed that rectal administration of suppositories with DHEA based on cocoa butter caused about 30% availability and after vaginal administration, only topical activity can be expected. By the addition of Tween 80 to the suppository mass availability of DHEA of about 35% from vaginal suppositories can be achieved.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Azarmi S. et al.: Current perspectives in dissolution testing of conventional and novel dosage forms. Int. J. Pharm. 328(1) 12 2007.

  • 2. Babar A. Fares H. M. Plakogiannis F. M.: In vitro release of testosterone from suppository bases and in vivo absorption studies in human males. J. Pharm. Sci. 82(4) 389 1993.

  • 3. Beral V. Bull D. Reeves G.: Endometrial cancer and hormonereplacement therapy in the Million Women Study. Lancet 365 1543 2005.

  • 4. Bergogne-Bérézin E. Bryskier A.: The suppository form of antibiotic administration: pharmacokinetics and clinical application.J. Antimicrob. Chemother. 43(2) 177 1999.

  • 5. Buster J.E. Casson P.R. (2000). Biology and use in therapeutic intervention. in Menopause: Biology and Pathobiology. Lobo R. A. Kelsey J. and Marcus R. (editors). San Diego: Academic Press; p 628.

  • 6. Casson P. R. et al.: Dehydroepiandrosterone (DHEA) replacement in postmenopausal women: Present status and future promise.Menopause 4 225 1997.

  • 7. Casson P. R. et al.: Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women. Am.J. Obstet. Gynecol. 169 1536 1993.

  • 8. Casson P. R. et al.: Replacement of dehydroepiandrosterone enhances T-lymphocyte insulin binding in postmenopausal women. Fertil Steril 63(5) 1027 1995.

  • 9. Castelo-Branco C. et al.: Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas 52(Suppl. 1) 46 2005.

  • 10. Chicco D. et al.: Correlation of in vitro and in vivo paracetamol availability from layered excipient suppositories. Int. J. Pharm. 189 147 1999.

  • 11. Czarnecki W. Kasperek R.: Patent RP Nr P337979 z 21.01.2000r.Biomed Wytwórnia Surowic i Szczepionek w Lublinie.

  • 12. Dal Zorro M. et al.: Effect of the surfactant on the availability of piroxicam as a poorly hydrosoluble drug from suppositories.Pharmazie 67(1) 37 2012.

  • 13. Ghorab D. Refai H. Tag R.: Preparation and evaluation of fenoterol hydrobromide suppositories. Drug Discov. Ther. 5(6) 311 2011.

  • 14. Hargoli S. et al.: Preparation and In vitro Evaluation of Naproxen Suppositories. Indian J. Pharm. Sci. 75(2) 143 2013.

  • 15. Kalmár É. et al.: Novel sample preparation method for surfactant containing suppositories: effect of micelle formation on drug recovery. J. Pharm. Biomed. Anal. 83 149 2013.

  • 16. Karavana S. Y. et al.: Dissolution and histological studies on ordidazole vaginal formulation. Acta Pharma. Sci. 52 430 2010.

  • 17. Labrie F. et al.: Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause 16(5) 923 2009.

  • 18. Labrie F. et al.: Intravaginal dehydroepiandrosterone (prasterone) a highly efficient treatment of dyspareunia. Climacteric 14(2) 282 2011.

  • 19. Labrie F. et al.: Intravaginal dehydroepiandrosterone (Prasterone) a physiological and highly efficient treatment of vaginal atrophy.Menopause 16(5) 907 2009.

  • 20. Labrie F. et al.: Is Dehydroepiandrosterone a hormone? J. Endocrinol. 187169 2005.

  • 21. Labrie F. et al.: Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J. Clin. Endocrinol. Metab. 82 2396 1997.

  • 22. Lynch C.: Vaginal estrogen therapy for the treatment of atrophic vaginitis. J. Womens Health (Larchmt) 18(10) 1595 2009.

  • 23. Nestler J. E. et al.: Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J. Clin. Endocrinol. Metab. 66 57 1988.

  • 24. Niraj et al.: Effect of Adjuvants on the Release Pattern of Suppositories Containing Paracetamol. RJCES 1(1) 19 2013.

  • 25. Odeniyi M. A. Jaiyeoba K. T.: Effects of interacting variables on the release properties of chloroquine and aminophylline suppositories.Trop. J. Pharm. Res. 3(1) 285 2004.

  • 26. Panjari M. Davis S.R.: DHEA for postmenopausal women: a review of the evidence. Maturitas 66(2) 172 2010.

  • 27. Panjari M. Davis S.R.: Vaginal DHEA to treat menopause related atrophy: a review of the evidence. Maturitas 70(1) 22 2011.

  • 28. Polish Pharmacopoeia IXth ed. vol. I PTF Warsaw (2011).

  • 29. Realdon N. et al.: Effects of surfactant characteristics on drug availability from suppositories. Pharmazie 63(6) 459 2008.

  • 30. Sah M. L. Saini T.R.: Formulation development and release studies of indomethacin suppositories. Indian J. Pharm. Sci. 70(4) 498 2008.

  • 31. Varshney H. M. Chatterjee A.: Formulation evaluation and in-vitro release characteristics of zaltoprofen suppositories. Asian J. Pharm.Clin. Res. 5(4) 235 2012.

  • 32. Varshney H. M. Tanwar Y. S.: Effect of different surfactants on the release pattern of cocoa butter suppositories containing flurbiprofen sodium. Acta Pharm. Sci. 52 129 2010.

  • 33. Verma P. et al.: Routes of drug administration. Int. J. Pharm. Studies Res. 1(1) 54 2010.

Journal information
Impact Factor

CiteScore 2018: 0.32

SCImago Journal Rank (SJR) 2018: 0.154
Source Normalized Impact per Paper (SNIP) 2018: 0.285

Cited By
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 354 209 3
PDF Downloads 128 78 2